FDA OKs Natroba
SILVER SPRING, Md. — The Food and Drug Administration has approved a new treatment for head lice, the agency said Tuesday.
The FDA approved Natroba (spinosad) topical suspension, made by ParaPro, a privately owned drug company based in Carmel, Ind. The drug is used to treat head lice infestation in patients ages 4 years and older.
“Natroba provides another option for the topical treatment of head lice infestations, which are especially prevalent in the pediatric population,” FDA Office of Drug Evaluation III director Julie Beitz said. “Head lice is a common problem among schoolchildren in the United States.”
Karl Matuszewski joins First DataBank
SOUTH SAN FRANCISCO, Calif. — Drug database provider First DataBank has appointed former Gold Standard/Elsevier editor-in-chief Karl Matuszewski as VP clinical and editorial knowledge-base services, the company said Tuesday.
In the new role, Matuszewski will guide editorial policy development for the creation and maintenance of First DataBank’s knowledge-base services and disease decision support products, including National Drug Data File Plus, OrderView Med Knowledge Base and related clinical modules.
“We are pleased to have Karl join the leadership at First DataBank,” First DataBank president and CEO Greg Dorn said. “His deep clinical expertise and knowledge of drug informatics will be of great value to First DataBank and will ensure that the clinical content we publish will continue to evolve to support our vision for innovative client solutions.”
IMS Health expands with SDI Health acquisition
NEW YORK — Healthcare market research firm IMS Health will buy privately held market research firm SDI Health, IMS said.
Terms of the transaction were not disclosed, but the deal would bring together two of the leading healthcare analytics companies. In terms of drug industry analytics, IMS focuses on drug sales and dispensed prescriptions, while SDI provides data on prescriptions written by physicians and other prescribers.
IMS, which has existed for more than 55 years and operates in more than 100 countries, said the acquisition would enable more robust patient and specialty analytics while allowing it to reach out to a broader set of stakeholders.